Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...
Promising Potential of Merus’s Petosemtamab in HNSCC: A Buy Recommendation
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...
Truist Financial Sticks to Its Buy Rating for Merus (MRUS)
In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on Merus (MRUS – Research Report). The company’s ...
Citigroup Issues Positive Forecast for Merus (NASDAQ:MRUS) Stock Price
Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...
Merus (NASDAQ:MRUS) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...
Merus Scores Its First FDA Approval For Lung Cancer Drug
Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...
Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...
The Pharma Letter2d
Positive early data on Merus’ petosemtamab
Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...
news.stocktradersdaily7d
Trend Tracker for (MRUS)
December 05, 2024, 04:52 am ET, BY Momei- Contributor, Stock Traders Daily| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) ...
The Pharma Letter6d
A first for Merus’ Bizengri with FDA nod
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Bizengri (zenocutuzumab-zbco; Zeno) from ...
AOL6d
Merus Scores Its First FDA Approval For Lung Cancer Drug
On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell ...
Nasdaq23d
Merus is Now Oversold (MRUS)
In trading on Monday, shares of Merus NV (Symbol: MRUS) entered into oversold territory, hitting an RSI reading of 29.5, after changing hands as low as $44.16 per share. By comparison, the current ...